Immunological persistence for 24 months following rapid immunization with 60 μg recombinant hepatitis B vaccine (saccharomyces cerevisiae) in adults

doi:10.3877/cma.j.issn.1674-1358.2026.04.007

Abstract

Abstract:

Objective

To investigate the 24 months immune persistence after rapid immunization with 60 μg recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (abbreviated as 60 μg hepatitis B vaccine) in adult recipients.

Methods

This observational study included adults enrolled in the accelerated hepatitis B vaccination program in Dayao County Center for Disease Control and Prevention,Yunnan Province, from March 2021 to April 2022, who received at least one dose of the 60 μg hepatitis B vaccine. Hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBsAb) and geometric mean concentration (GMC) were detected to evaluate the 24 months immunological persistence of the vaccine. The 305 recipients were divided into four groups based on their HBsAb levels at 1 month post-immunization: group with HBsAb 10-＜100 mIU/ml, group with HBsAb 100-＜1 000 mIU/ml, group with HBsAb 1 000-＜10 000 mIU/ml and group with HBsAb≥10 000 mIU/ml. HBsAb positivity rates and HBsAb GMC of patients among different groups were analyzed by Chi-square test and variance analysis (ANOVA), respectively.

Results

Among the 305 enrolled subjects, 249 had HBsAb≥ 10 mIU/ml at 24 months after full-course immunization, with a positive rate of 81.64%, and the HBsAb GMC was 121.97 mIU/ml (95%CI: 98.41-151.16). After 24-month follow-up, the positive rates of HBsAb subgroups 10-＜100 mIU/ml, 100-＜1 000 mIU/ml, 1 000-＜10 000 mIU/ml and≥10 000 mIU/ml were 49.25% (33/67), 86.49% (128/148), 96.92% (63/65) and 100.00% (25/25), respectively; their corresponding GMC values were 39.26 mIU/ml (95%CI: 23.41-65.84), 75.71 mIU/ml (95%CI: 57.91-98.97), 214.80 mIU/ml (95%CI: 169.38-272.41) and 1 503.74 mIU/ml (95%CI: 772.98-2 925.35).

Conclusions

The 60 μg hepatitis B vaccine demonstrates excellent immunogenicity persistence when administered in the adult rapid immunization program.

Key words: Hepatitis B vaccine, Rapid immunization program, Immune persistence

Haitao Yang, Haoming Zhang, Jingshan Zheng, Huayu Li, Rui Zhang, Xiaoqiang Liu. Immunological persistence for 24 months following rapid immunization with 60 μg recombinant hepatitis B vaccine (saccharomyces cerevisiae) in adults[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2026, 20(04): 246-251.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2026.04.007

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2026/V20/I04/246

Figures/Tables 4

References 42

[1]	World Health Organization. Global hepatitis report 2024[EB/OL]. 2024.
[2]	Zheng H, Wang Y, Wang FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac,2024,51:101193.
[3]	Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries[J]. CA Cancer J Clin,2026,76(4):e70090.
[4]	Wen B, Te L, Bai C, et al. Relative contribution of Hepatitis B and C Viruses in primary liver cancer in China: a systematic review and Meta-analysis[J]. J Infect,2024,06298.
[5]	Duo H, You J, Du S, et al. Liver cirrhosis in 2021: Global burden of disease study[J]. PLoS One,2025,20(7):e0328493.
[6]	Jia X, Fei W, Nai-Kei W, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol,2019,71(1):212-221.
[7]	尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志,2023,26(3):457-478.
[8]	Bai XX, Chen L, Liu X, et al. Adult hepatitis B virus vaccination coverage in China from 2011 to 2021: A systematic review[J]. Vaccines,2022,10(6):900.
[9]	张国民, 孙校金, 王富珍, 等. 中国18-59岁人群乙型病毒性肝炎流行病学特征分析及乙型肝炎疫苗免疫策略探讨[J]. 中国疫苗和免疫,2013,19(3):266-270.
[10]	冯艺, 吕静静, 颜丙玉, 等. 2019-2021年山东省成人乙型肝炎疫苗全程接种完成情况分析[J]. 中国预防医学杂志,2024,25(7):873-877.
[11]	张婷, 刘聪, 郑莉, 等. 2020年湖北省1-69岁人群乙型肝炎血清流行病学调查[J]. 中国疫苗和免疫,2022,28(2):154-158.
[12]	Vesikari T, Langley JM, Segall N, et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial[J]. Lancet Infect Dis,2021,21(9):1271-1281.
[13]	Janssen JM, Jackson S, Heyward WL, et al. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age[J]. Vaccine,2015,33(31):3614-3618.
[14]	Chowdhury A, Santra A, Habibullah CM, et al. Immune response to an indigenously developed r-hepatitis B vaccine in mixed population: study of an accelerated vaccination schedule[J]. World J Gastroenterol,2005,11(7):1037-1039.
[15]	Herck KV, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance[J]. Sex Transm Infect,2007,83(6):426-432.
[16]	Hyer R, McGuire DK, Xing B, et al. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018,using a toll-like receptor 9 agonist adjuvant in adults[J]. Vaccine,2018,36(19):2604-2611.
[17]	聂黎, 庞星火, 张政, 等. 不同种类和剂量乙型肝炎疫苗成年人快速免疫效果观察[J]. 中华流行病学杂志,2017,38(9):1151-1155.
[18]	Yao J, Li J, Chen YD. The response of hepatitis B vaccination on seronegative adults with different vaccination schedules[J]. Hum Vaccin Immunother,2015,11(5):1102-1107.
[19]	Wang H, Cai B, Rao D, et al. Rapid immunization effects of a new type of 60 μg hepatitis B vaccine compared with traditional 20 μg hepatitis B vaccines in adults[J]. Hum Vaccin Immunother,2016,12(11):2921-2926.
[20]	Wang ZZ, Li MQ, Wang P, et al. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China[J]. Vaccine,2016,34(8):1034-1039.
[21]	Feng Y, Shi X, Shi J, et al. Immunogenicity, antibody persistence, and safety of the 60 μg hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial[J]. Expert Rev Vaccines,2017,16(10):1045-1052.
[22]	Yao T, Shao ZH, Wu L, et al. Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: a 3-year follow-up study in China[J]. Vaccine,2021,39(18):2537-2544.
[23]	Yao T, Li Y, Zhang Y, et al. Immunogenicity, safety, and persistence induced by triple- and standard-strength 4-dose hepatitis B vaccination regimens in patients receiving hemodialysis[J]. J Infect Dis,2025,231(4):1049-1059.
[24]	Feng YL, Yao T, Han YJ, et al. Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: A randomized, double-blinded, parallel-controlled trial[J]. Expert Rev Vaccines,2021,20(6):743-751.
[25]	Feng YL, Chen ZZ, Xie RX, et al. Immunogenicity and safety of 4 intramuscular standard-dose regimen and high-dose regimen in people living with HIV: A randomized, parallel-controlled trial[J]. Expert Rev Vaccines,2022,21(6):861-868.
[26]	Shi J, Feng YL, Gao LY, et al. Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial[J]. Vaccine,2017,35(18):2443-2448.
[27]	冯超, 牛玉坚, 陈兴国, 等. 不同乙型肝炎疫苗接种方案在入伍新兵中的免疫效果观察[J]. 解放军医学杂志,2018,43(11):968-971.
[28]	邓素, 张建国. 不同剂量重组乙型肝炎疫苗(CHO细胞)采用两种免疫接种程序的对照研究[J]. 实用预防医学,2011,18(3):446-448.
[29]	袁跃彬, 王仲倩, 马西平, 等. 不同剂量重组酵母乙型肝炎疫苗成人免疫后效果比较[J]. 解放军预防医学杂志,2003,21(3):176-179.
[30]	段耀华. 不同剂量乙型肝炎疫苗免疫效果及安全性研究[J]. 山西医科大学学报,2004,35(3):272-274.
[31]	Li J, Meng F, Zheng J, et al. Immune persistence induced by three doses of 60 μg hepatitis B vaccine in non-responders following standard primary vaccination in Chinese adults[J]. Hum Vaccin Immunother,2021,17(8):2762-2767.
[32]	唐广心, 叶发忠, 刘晓军, 等. 低/无应答者接种60 μg乙肝疫苗后抗体水平衰减及其影响因素研究[J]. 疾病监测与控制,2015,9(5):307-308.
[33]	王桂红, 齐桂华, 张金华. 重组酵母乙型肝炎疫苗(60 μg)抗-HBs阳转率及接种反应[J]. 中国生物制品学杂志,2013,26(7):994-996.
[34]	唐广心, 叶发忠, 刘晓军, 等. 低/无应答医务人员接种60 μg乙肝疫苗1年后的免疫效果观察[J]. 医学理论与实践,2015,28(3):296-297, 300.
[35]	陈胜玉, 陈颖峰, 叶品凯, 等. 乙型肝炎疫苗基础免疫无应答成人复种1剂次60 μg乙型肝炎疫苗后10年免疫持久性[J]. 中国疫苗和免疫,2025,31(2):185-188.
[36]	Wang ZZ, Gao YH, Wang P, et al. Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study[J]. Hum Vaccin Immunother,2018,14(6):1475-1482.
[37]	杨娅春, 刘晓强, 郑景山, 等. 60 μg乙型肝炎疫苗快速免疫程序在≥16岁健康易感人群中免疫原性和安全性的非劣效临床试验[J]. 中国疫苗和免疫,2022,28(6):673-678.
[38]	费迎明, 兰少波, 王建忠, 等. 成人接种60 μg重组乙型肝炎疫苗免疫效果观察[J]. 预防医学,2018,30(3):284-288.
[39]	吕静静, 张丽, 颜丙玉, 等. 乙型肝炎疫苗初次免疫成年正常应答和高应答者3年抗体持久性观察[J]. 中华预防医学杂志,2016,50(6):478-483.
[40]	World Health Organization. Hepatitis B vaccines: WHO position paper--July 2017[J]. Wkly Epidemiol Rec,2017,92(27):369-392.
[41]	Yang L, Yao J, Li J, et al. Suitable hepatitis B vaccine for adult immunization in China[J]. Ummunol Res,2016,64(1):242-250.
[42]	Chaves SS, Fischer G, Groeger J, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth[J]. Vaccine,2012,30(9):1644-1649.

人口学特征	全分析数据集对象（343例）	失访对象（57例）	χ²值	P值
性别			0.359	0.549
男	153（44.61）	23（40.35）
女	190（55.39）	34（59.65）
免疫时年龄			3.827	0.281
16～29岁	40（11.67）	9（15.79）
30～39岁	66（19.24）	16（28.07）
40～49岁	110（32.07）	14（24.56）
≥ 50岁	127（37.03）	18（31.58）

人口学特征	全分析数据集对象（343例）	失访对象（57例）	χ²值	P值
性别			0.359	0.549
男	153（44.61）	23（40.35）
女	190（55.39）	34（59.65）
免疫时年龄			3.827	0.281
16～29岁	40（11.67）	9（15.79）
30～39岁	66（19.24）	16（28.07）
40～49岁	110（32.07）	14（24.56）
≥ 50岁	127（37.03）	18（31.58）

时间	例数	阳性率[例（%）]	GMC [mIU/ml（95%CI）]
免疫后1个月	305	305（100.00）	483.65（387.19～604.14）
免疫后24个月	305	249（81.64）	121.97（98.41～151.16）
统计量		χ² = 61.661^a	F = 8.653
P值		＜ 0.001	＜ 0.001

时间	例数	阳性率[例（%）]	GMC [mIU/ml（95%CI）]
免疫后1个月	305	305（100.00）	483.65（387.19～604.14）
免疫后24个月	305	249（81.64）	121.97（98.41～151.16）
统计量		χ² = 61.661^a	F = 8.653
P值		＜ 0.001	＜ 0.001

HBsAb免疫1个月（mIU/ml）	例数	HBsAb阳性率[例（%）]	HBsAb GMC[mIU/ml（95%CI）]
10～＜ 100	67	33（49.25）	39.26（23.41～65.84）
100～＜ 1 000	148	128（86.49）	75.71（57.91～98.97）
1 000～＜ 10 000	65	63（96.92）	214.80（169.38～272.41）
≥ 10 000	25	25（100.00）	1 503.74（772.98～2 925.35）
统计量		χ² = 66.899	F = －42.120
P值		＜ 0.001	＜ 0.001
统计量₁		χ² = 33.994	F = －2.282
P₁值		＜ 0.001	0.115
统计量₂		χ² = 37.798	F = －6.063
P₂值		＜ 0.001	＜ 0.001
统计量₃		χ² = 20.124	F = －8.884
P₃值		＜ 0.001	＜ 0.001
统计量₄		χ² = 5.311	F = －3.764
P₄值		0.021	＜ 0.001
统计量₅		χ² = 3.820	F = －8.547
P₅值		0.051	＜ 0.001
统计量₆		χ² = 0.787	F = －5.663
P₆值		0.375	＜ 0.001

Please choose a citation manager

Content to export